Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events
Item 8.01 Other Events
On March20, 2017, Esperion Therapeutics,Inc. issued a press
release titled, Esperion Announces FDA Confirmation Regarding
Regulatory Pathway to Approval for an LDL-C Lowering Indication
for Bempedoic Acid (the Press Release). A copy of the Press
Release is filed herewith as Exhibit99.1 and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release dated March20, 2017. |
***
About Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid. Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information
Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session down -5.98 at 23.67 with 9,486,087 shares trading hands.
